Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Exagen Inc.
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
11 mars 2025 08h00 HE
|
Exagen Inc.
Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over 40%Commercialized new biomarkers to enhance clinical utility of...
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
25 févr. 2025 16h05 HE
|
Exagen Inc.
CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31,...
Exagen Inc. to Participate in Upcoming Investor Conferences
04 févr. 2025 16h05 HE
|
Exagen Inc.
CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming...
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
12 janv. 2025 12h00 HE
|
Exagen Inc.
New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted...
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
12 déc. 2024 09h00 HE
|
Exagen Inc.
CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000th AVISE CTD test, marking a significant...
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
14 nov. 2024 16h30 HE
|
Exagen Inc.
CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus...
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
13 nov. 2024 16h05 HE
|
Exagen Inc.
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following...
Exagen Inc. Reports Third Quarter 2024 Results
12 nov. 2024 08h00 HE
|
Exagen Inc.
Expanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three quarters of 2024Revenue in line with expectations, excluding one-time adjustments CARLSBAD,...
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
29 oct. 2024 16h05 HE
|
Exagen Inc.
CARLSBAD, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended September 30, 2024,...
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
21 oct. 2024 16h05 HE
|
Exagen Inc.
CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College...